Clinical Trial Update: A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a combination of HF10 with ipilimumab in unresectable or metastatic malignant melanoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• HF10
• ipilimumab (ipilimumab)

Snippet

Sponsor: Takara Bio Inc. | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED